New Experimental HCV Drugs in Development

HCV Protease Inhibitor SCH-503034 | Combo Treatment SCH-503034
HCV Protease Inhibitor VX-950
Valopicitabine (NM 2833) +/- Peginterferon +/- Ribavirin
Consensus Interferon + Gamma Interferon +/- Ribavirin
High-dose (double dose) Pegasys + Ribavirin
Albuferon Plus Ribavirin




HCV Protease Inhibitor SCH-503034 and Combo Treatment SCH-503034  Top

The Era of Protease Inhibitors for the Treatment of HCV: An Overview of SCH 503034 - 11/23/05

SCH 503034, an Experimental HCV Protease Inhibitor from Schering Plough, Shows Potent Anti-HCV Activity in Patients Previously Failing on Peginterferon Alfa - 11/14/05

Pharmacokinetics and Safety of the Experimental, Oral HCV Protease Inhibitor SCH 503034 in Healthy Subjects - 11/14/05

SCH 503034 Suppresses Polyprotein Maturation and Enhances the Antiviral Activity of Interferon Alfa-2b - 11/14/05

HCV Protease Ihibitor VX-950  Top

Final Results of a Phase 1B, Multiple-dose Study of VX-950, a Hepatitis C Virus Protease Inhibitor - 11/14/05

Valopicitabine (NM 283)  Top

Randomized Trial of Valopicitabine (NM 283), Alone or with Peginterferon, vs Retreatment with Peginterferon Plus Ribavirin in Nonresponders to Peginterferon Alfa - 11/14/05

No Effect of Pegylated Interferon Alfa-2b (PegIntron) on the Pharmacokinetics of Valopicitabine (NM 283) in Chronic HCV Patients - 11/14/05

Consensus Interferon + Gamma Interferon +/- Ribavirin  Top

Consensus Interferon in Combination with Gamma Interferon and/or Ribavirin Results in a Significant Virologic Response in Hepatitis C Genotype 1 Patients - 11/14/05

Albuferon Plus Ribavirin  Top

Albuferon Plus Ribavirin in Nonresponders to Interferon Therapy - 11/18/05


High-dose (double dose) Pegasys + Ribavirin  Top

High-dose Pegylated interferon-alfa-2a (Pegasys): A Safety Evaluation - 11/23/05

<--- Return to the 56th AASLD Main Page